ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B

Tang, Yanhua; Fan, Rong; Lan, Zhixian; Xie, Qing; Zhang, Jiping; Liang, Xieer; Wang, Hao; Tan, Deming; Cheng, Jun; Chen, Shijun; Ning, Qin; Bai, Xuefan; Xu, Min; Chen, Xinyue; Niu, Junqi; Shi, Junping; Ren, Hong; Gao, Zhiliang; Wang, Maorong; Dou, Xiaoguang; Hou, Jinlin*; Sun, Jian*北京大学; 华中科技大学; 吉林大学; 南方医科大学; 上海交通大学; 中国医科大学; 中山大学; 6
Journal of Medical Virology2023-2DOI: 10.1002/jmv.28501
8阅读
引用收藏
分享

摘要

Data on the dynamic changes in chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD) during antiviral therapy are scarce. We aimed to investigate the evolution of NAFLD status change in CHB patients treated with nucleos(t)ide analogues (NAs) and its influence on therapeutic outcomes. This retrospective study included 164 HBeAg-positive CHB patients from a randomized controlled trial who were treated with NAs for 104 weeks and underwent paired liver biopsies. Histological evaluation was performed at baseline and Week 104. The patients were divided into four groups according to NAFLD status changes. From baseline to Week 104, the overall percentage of CHB patients with concurrent NAFLD increased from 17.1% to 26.2% (p = 0.044). Among them, 7 of 28 patients (25.0%) with NAFLD at baseline showed NAFLD remission at week 104, while 22 of 136 patients (16.2%) without NAFLD at baseline developed new-onset NAFLD. In subgroup analyses, the new-onset and sustained NAFLD groups showed significantly lower rates of biochemical response at week 104 as compared to the sustained non-NAFLD group (77.3% and 57.1% vs. 93.9%, respectively; all p < 0.05), as well as fibrosis improvement (31.8% and 42.9% vs. 69.3%, respectively; all p < 0.05). NAFLD status changes did not influence the virological response, HBeAg seroconversion, and necroinflammation improvement (all p > 0.05). In HBeAg-positive CHB patients receiving NAs therapy, new-onset and sustained NAFLD may counteract the benefits of antiviral therapy, reducing the rate of biochemical response and fibrosis improvement.

学科与关键词

关键词
fatty liverhepatitis B virusliver biopsynucleos(t)ide analogues
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Medical Virology
发表日期
2023-02
卷期
第 95 卷, 第 2 期
DOI
10.1002/jmv.28501
语言
ENGLISH
成果收录
SCIE
资助标注
Local Innovative and ResearchTeams Project of Guangdong Pearl River Talents Program; National Natural Science Foundation of China

作者

  • T

    Tang, Yanhua (第一作者)

    southern med univ

  • F

    Fan, Rong

    southern med univ

查看全部 22 位作者收起作者
  • L

    Lan, Zhixian

    southern med univ

  • X

    Xie, Qing

    ruijin hosp · shanghai jiao tong univ

  • Z

    Zhang, Jiping

  • L

    Liang, Xieer

    southern med univ

  • W

    Wang, Hao

    peking univ

  • T

    Tan, Deming

  • C

    Cheng, Jun

    beijing ditan hosp

  • C

    Chen, Shijun

  • N

    Ning, Qin

    huazhong univ sci & technol

  • B

    Bai, Xuefan

  • X

    Xu, Min

  • C

    Chen, Xinyue

  • N

    Niu, Junqi

    jilin univ

  • S

    Shi, Junping

    6

  • R

    Ren, Hong

    2 · chongqing med univ

  • G

    Gao, Zhiliang

    sun yat sen univ

  • W

    Wang, Maorong

    81st pla hosp

  • D

    Dou, Xiaoguang

    china med univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

  • S

    Sun, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417